TN2015000027A1 - Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor - Google Patents

Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Info

Publication number
TN2015000027A1
TN2015000027A1 TNP2015000027A TN2015000027A TN2015000027A1 TN 2015000027 A1 TN2015000027 A1 TN 2015000027A1 TN P2015000027 A TNP2015000027 A TN P2015000027A TN 2015000027 A TN2015000027 A TN 2015000027A TN 2015000027 A1 TN2015000027 A1 TN 2015000027A1
Authority
TN
Tunisia
Prior art keywords
inhibitor
optionally
pi3k
raf
egfr
Prior art date
Application number
TNP2015000027A
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000027(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2015000027A1 publication Critical patent/TN2015000027A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TNP2015000027A 2012-08-07 2015-01-19 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor TN2015000027A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (fr) 2012-08-07 2013-08-05 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Publications (1)

Publication Number Publication Date
TN2015000027A1 true TN2015000027A1 (en) 2016-06-29

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000027A TN2015000027A1 (en) 2012-08-07 2015-01-19 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Country Status (39)

Country Link
US (1) US9474754B2 (fr)
EP (2) EP2882440B1 (fr)
JP (3) JP6342396B2 (fr)
KR (1) KR102112885B1 (fr)
CN (1) CN104519887B (fr)
AR (1) AR092045A1 (fr)
AU (1) AU2013299841B8 (fr)
CA (1) CA2879548C (fr)
CL (1) CL2015000294A1 (fr)
CO (1) CO7200273A2 (fr)
CY (1) CY1122143T1 (fr)
DK (1) DK2882440T3 (fr)
EA (1) EA028420B1 (fr)
EC (1) ECSP15008695A (fr)
ES (1) ES2717911T3 (fr)
GT (1) GT201500025A (fr)
HK (2) HK1204976A1 (fr)
HR (1) HRP20190537T1 (fr)
HU (1) HUE042877T2 (fr)
IL (1) IL236934B (fr)
IN (1) IN2015DN00450A (fr)
JO (1) JOP20130236B1 (fr)
LT (1) LT2882440T (fr)
MA (1) MA37829A1 (fr)
MX (1) MX359403B (fr)
MY (1) MY176031A (fr)
NZ (1) NZ703940A (fr)
PE (2) PE20150673A1 (fr)
PH (1) PH12015500246A1 (fr)
PL (1) PL2882440T3 (fr)
PT (1) PT2882440T (fr)
RS (1) RS58734B1 (fr)
SG (1) SG11201500321YA (fr)
SI (1) SI2882440T1 (fr)
TN (1) TN2015000027A1 (fr)
TR (1) TR201904980T4 (fr)
TW (1) TWI607754B (fr)
UA (1) UA115786C2 (fr)
WO (1) WO2014025688A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102112885B1 (ko) * 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물
NZ712184A (en) 2013-03-21 2020-01-31 Array Biopharma Inc Combination therapy comprising a b-raf inhibitor and a second inhibitor
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
PL3155126T3 (pl) * 2014-06-16 2019-01-31 Worldwide Innovative Network Sposób wybierania spersonalizowanej terapii potrójnej do leczenia nowotworu
WO2016193955A1 (fr) * 2015-06-04 2016-12-08 Giorgio Stassi Combinaisons d'inhibiteurs de kinase pour le traitement du cancer colorectal
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
WO2017037573A1 (fr) * 2015-08-28 2017-03-09 Novartis Ag Combinaison pharmaceutique comprenant l'inhibiteur de pi3k alpélisib et l'inhibiteur de b-raf dabrafénib ; l'utilisation de cette combinaison dans le traitement ou la prévention du cancer
WO2017066664A1 (fr) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Polythérapie comprenant un inhibiteur de raf pour le traitement du cancer colorectal
UA125436C2 (uk) * 2016-06-03 2022-03-09 Еррей Біофарма, Інк. Фармацевтичні комбінації
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
CA3069564A1 (fr) * 2017-08-03 2019-02-07 Novartis Ag Association therapeutique d'un inhibiteur de tyrosine kinase d'egfr de troisieme generation et d'un inhibiteur de raf
EP4364798A2 (fr) 2018-10-05 2024-05-08 Annapurna Bio Inc. Composés et compositions pour le traitement d'états associés à l'activité du récepteur apj
TW202043225A (zh) * 2019-01-25 2020-12-01 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (fr) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
WO2023145530A1 (fr) * 2022-01-27 2023-08-03 国立大学法人東北大学 Agent thérapeutique contre le cancer
WO2023230554A1 (fr) 2022-05-25 2023-11-30 Pfizer Inc. Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
WO2024073364A1 (fr) * 2022-09-26 2024-04-04 Beigene, Ltd. Associations d'un inhibiteur de b-raf et d'un anticorps anti-egfr pour le traitement du cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
SG10201402917XA (en) * 2009-08-24 2014-08-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012008519A2 (pt) * 2009-10-12 2016-04-05 Glaxosmithkline Llc combinação
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
JP2013542228A (ja) * 2010-11-08 2013-11-21 ノバルティス アーゲー Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
CN104185631A (zh) 2011-11-10 2014-12-03 纪念斯隆-凯特琳癌症中心 用2-氨基-4H-萘并[1,2-b]吡喃-3-甲腈治疗卵巢癌
CN103917236A (zh) * 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
KR102112885B1 (ko) * 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물

Also Published As

Publication number Publication date
PT2882440T (pt) 2019-04-23
AR092045A1 (es) 2015-03-18
SG11201500321YA (en) 2015-04-29
EA028420B1 (ru) 2017-11-30
JP6974669B2 (ja) 2021-12-01
MA37829A1 (fr) 2017-01-31
ES2717911T3 (es) 2019-06-26
TWI607754B (zh) 2017-12-11
MX359403B (es) 2018-09-26
PE20150673A1 (es) 2015-05-20
KR20150040905A (ko) 2015-04-15
MY176031A (en) 2020-07-22
CL2015000294A1 (es) 2015-05-08
AU2013299841B8 (en) 2017-01-05
US9474754B2 (en) 2016-10-25
EP2882440A1 (fr) 2015-06-17
JOP20130236B1 (ar) 2021-08-17
PH12015500246B1 (en) 2015-03-30
MX2015001732A (es) 2015-06-03
JP2018109022A (ja) 2018-07-12
UA115786C2 (uk) 2017-12-26
US20150265616A1 (en) 2015-09-24
AU2013299841A1 (en) 2015-02-12
CY1122143T1 (el) 2020-11-25
DK2882440T3 (da) 2019-05-06
AU2013299841B2 (en) 2016-11-24
RS58734B1 (sr) 2019-06-28
EP2882440B1 (fr) 2019-02-27
BR112015002384A8 (pt) 2019-07-30
CA2879548A1 (fr) 2014-02-13
JP2020019780A (ja) 2020-02-06
JP2015524472A (ja) 2015-08-24
HRP20190537T1 (hr) 2019-06-28
ECSP15008695A (es) 2019-03-29
GT201500025A (es) 2017-09-28
JP6595024B2 (ja) 2019-10-23
KR102112885B1 (ko) 2020-05-19
HUE042877T2 (hu) 2019-07-29
TW201410247A (zh) 2014-03-16
SI2882440T1 (sl) 2019-05-31
EP3574904A1 (fr) 2019-12-04
CO7200273A2 (es) 2015-02-27
NZ703940A (en) 2018-04-27
HK1211831A1 (en) 2016-06-03
TR201904980T4 (tr) 2019-05-21
CN104519887A (zh) 2015-04-15
BR112015002384A2 (pt) 2017-07-04
AU2013299841A8 (en) 2017-01-05
PL2882440T3 (pl) 2019-07-31
CA2879548C (fr) 2020-07-21
WO2014025688A1 (fr) 2014-02-13
LT2882440T (lt) 2019-04-25
PH12015500246A1 (en) 2015-03-30
PE20191655A1 (es) 2019-11-07
IN2015DN00450A (fr) 2015-06-26
EA201590332A1 (ru) 2015-06-30
CN104519887B (zh) 2017-06-27
JP6342396B2 (ja) 2018-06-13
IL236934B (en) 2018-11-29
HK1204976A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2016008362A (es) Combinaciones farmaceuticas.
AU2011328009A8 (en) Compounds and methods for treating pain
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
CA3019531A1 (fr) Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicite a mediation cellulaire dependante d'un anticorps (adcc) pour le traitement du cancer
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
PH12015501002A1 (en) Treatment of cancer with pomalidomide in a renally impaired subject
UA115250C2 (uk) Фармацевтичні комбінації
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
WO2014155268A3 (fr) Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
UA86338U (ru) Способ лечения беременных с гестационным диабетом
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності